8-K: Salarius Regains Nasdaq Bid Price Compliance, Merger Progresses

Salarius Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement while continuing to work towards compliance with the Equity Standard, as its merger with Decoy Therapeutics advances.

Summary

• Salarius Pharmaceuticals, Inc. (Salarius) received notification on September 4, 2025, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.
• To achieve this, Salarius common stock maintained a closing bid price of $1.00 per share or more for at least 10 consecutive business days.
• Nasdaq will subject Salarius to a Mandatory Panel Monitor for one year from September 4, 2025, meaning any future non-compliance with the Bid Price Rule will lead to a delisting determination letter.
• Salarius remains noncompliant with Nasdaq Listing Rule 5550(b)(1), the Equity Standard, and has until October 20, 2025, to achieve compliance.
• The company previously announced a definitive merger agreement with Decoy Therapeutics, Inc. on January 13, 2025, which, if consummated, will result in the combined company being named Decoy Therapeutics.
• The combined company will be led by Decoy's Co-founders, Chief Executive Officer Frederick Rick Pierce and Chief Scientific Officer Barbara Hibner, along with other Decoy executives and Salarius's Acting CEO and CFO Mark Rosenblum.
• Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to an Investigational New Drug (IND) application filing with the U.S. Food and Drug Administration (FDA) within the next 12 months.
• Other Decoy programs include a broad-acting antiviral against flu, COVID-19, and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers.
• The combined company intends to incorporate Salarius's oral small molecule protein degrader SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACs) drug candidate.
• Data may be reported from an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center evaluating Salarius's seclidemstat as a potential treatment for myelodysplastic syndrome and chronic myelomonocytic leukemia.

Sentiment

Score: 6

Explanation: The regaining of Nasdaq bid price compliance is a positive step, and the merger with Decoy Therapeutics brings a promising pipeline and technology platform. However, the continued non-compliance with the Nasdaq Equity Standard and the associated risks temper the overall sentiment.

Positives

• Regained compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5550(a)(2)) on September 4, 2025, by maintaining a closing bid price of $1.00 or more for 10 consecutive business days.
• Progressing with the planned merger with Decoy Therapeutics, which is expected to facilitate multiple value-creating inflection points with Decoy's IMP3ACT platform and pipeline.
• Decoy Therapeutics has attracted financing from institutional investors and significant non-dilutive capital from sources like the Massachusetts Life Sciences Seed Fund, Google AI startup program, NVIDIA Inception program, and a QuickFire Challenge award from BARDA through BLUE KNIGHT.
• The combined company will have a diversified pipeline targeting unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications.
• Plans to advance Decoy's lead asset, a pan-coronavirus antiviral, to an IND application filing with the FDA within the next 12 months.
• Intends to incorporate Salarius's SP-3164 into a highly targeted peptide-based PROTAC drug candidate, leveraging both companies' assets.

Negatives

• Salarius remains noncompliant with Nasdaq Listing Rule 5550(b)(1), the Equity Standard, with a deadline of October 20, 2025, to achieve compliance.
• Subject to a Mandatory Panel Monitor for one year from September 4, 2025, meaning any future non-compliance with the Bid Price Rule will lead to a delisting determination letter without further opportunity for an exception.

Risks

• Risk that conditions to the closing of the proposed merger are not satisfied, including uncertainties as to the timing of consummation.
• The ability of each of Salarius and Decoy to consummate the merger.
• Risks and uncertainties related to Salarius's ability to regain compliance with Nasdaq continued listing standards in the required timeframe, specifically the Equity Standard.
• Risks related to the combined company's ability to satisfy initial listing standards in the required timeframe.
• Salarius may not receive any additional extensions from Nasdaq if it is unable to regain compliance within the required timeframe.
• Risks related to Salarius's ability to estimate and manage its operating expenses and its expenses associated with the proposed merger pending the closing.
• Risks that the combined company will not achieve the synergies expected from the proposed merger.
• Risks that Salarius and the combined company will not obtain sufficient financing to execute on their business plans.
• Risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT platform.

Future Outlook

The combined company, Decoy Therapeutics, expects to advance its lead pan-coronavirus antiviral asset to an IND application filing with the FDA within the next 12 months and make progress on other programs, including a broad-acting antiviral and a peptide drug conjugate for GI cancers. Data from an investigator-initiated Phase 1/2 clinical study of Salarius's seclidemstat may also be reported during this time.

Management Comments

• "Salarius has achieved one of the milestones in regaining compliance with all Nasdaq continued listing standards."

Industry Context

The planned merger with Decoy Therapeutics positions the combined entity in the rapidly evolving biopharmaceutical space, leveraging advanced platforms like machine learning and AI for peptide conjugate therapeutics. This aligns with a broader industry trend towards targeted therapies and innovative drug discovery methods, particularly in areas like antivirals and oncology, where there are significant unmet medical needs. Decoy's non-dilutive funding from sources like Google AI and NVIDIA Inception highlights the increasing integration of technology and data science in drug development.

Comparison to Industry Standards

• The regaining of Nasdaq bid price compliance is a standard requirement for listed companies, indicating a return to a minimum market valuation threshold. Many small-cap biotechs face similar challenges in maintaining listing standards.
• Decoy Therapeutics' use of machine learning and AI (IMP3ACT platform) for rapid computational design and manufacturing of peptide conjugate therapeutics is consistent with cutting-edge approaches seen in companies like Recursion Pharmaceuticals or BenevolentAI, which also leverage AI for drug discovery.
• The focus on pan-coronavirus, broad-acting antivirals (flu, COVID-19, RSV), and GI oncology aligns with significant areas of unmet medical need and active research within the biopharmaceutical industry, comparable to pipelines at companies like Gilead Sciences (antivirals) or various oncology-focused biotechs.
• Attracting non-dilutive capital from sources like BARDA (through BLUE KNIGHT) is a strong validation for preclinical-stage companies, similar to how other biotechs secure government or foundation grants for critical public health initiatives.

Management Changes

Stakeholder Impact

• Shareholders: Regaining bid price compliance reduces immediate delisting risk, but the Equity Standard non-compliance remains a concern. The merger with Decoy Therapeutics offers potential for future value creation through a new pipeline and technology, but also introduces risks associated with the transaction and integration.
• Employees: The combined company will be led by Decoy's co-founders and executives, with Salarius's Acting CEO/CFO joining, indicating a significant shift in leadership and potential changes for existing Salarius employees.
• Customers/Patients: The combined company's focus on developing new therapeutics for respiratory infectious diseases and GI cancers could eventually benefit patients in need of new treatment options.

Next Steps

• Salarius must achieve compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by October 20, 2025.
• The combined company (Decoy Therapeutics) expects to advance its lead pan-coronavirus antiviral asset to an IND application filing with the FDA within the next 12 months.
• Progress will be made on other Decoy programs, including a broad-acting antiviral and a peptide drug conjugate targeting GI cancers.
• Data may be reported from an investigator-initiated Phase 1/2 clinical study of Salarius's seclidemstat at MD Anderson Cancer Center.
• Consummation of the merger with Decoy Therapeutics, subject to closing conditions.

Key Dates

Recommendation

While regaining Nasdaq bid price compliance is a positive, the company still faces a critical deadline for the Equity Standard. The proposed merger with Decoy Therapeutics presents a promising new pipeline and technology, but it is still preclinical, and the transaction itself carries execution risks. Investors should hold to monitor the outcome of the Equity Standard compliance and the progress of the merger and Decoy's pipeline development.

Keywords

Nasdaq compliance, minimum bid price, Equity Standard, Salarius Pharmaceuticals, Decoy Therapeutics, merger agreement, biopharmaceutical, peptide conjugate therapeutics, IMP3ACT platform, antiviral, GI cancers, SP-3164, PROTACs, seclidemstat, MD Anderson, FDA, IND application, delisting risk